SK Pharmaceuticals

SK Biopharmaceuticals is a global pharmaceutical company headquartered in South Korea that focuses on the discovery and development of treatments for central nervous system (CNS) disorders and oncology. The company achieved a significant milestone with the FDA approval of Xcopri (cenobamate) for the treatment of partial-onset seizures in adults, which it commercializes directly in the United States through its subsidiary, SK Life Science. Beyond its established CNS portfolio, the company is aggressively expanding into new modalities, including radiopharmaceutical therapy (RPT) and targeted protein degradation (TPD). SK Biopharmaceuticals leverages an AI-driven drug discovery platform to accelerate its pipeline and maintains strategic partnerships with global firms like Ono Pharmaceutical and Angelini Pharma. As part of the SK Group, one of South Korea's largest conglomerates, the company integrates R&D excellence with a robust global commercial infrastructure.